INTRODUCTION {#sec0005}
============

Alzheimer's disease (AD) is a devastating neurodegenerative pathology characterized by the progressive decline of cognitive functions. The accumulation of intracellular aggregates of tau protein in the neurofibrillary tangles and of extracellular aggregates of a set of polypeptides called amyloid-β peptides (Aβ) in the senile plaques \[[@ref001]\] are the major histological hallmarks of AD. Aβ peptides are generated from a large transmembrane protein, the amyloid-β protein precursor (AβPP) through its sequential cleavage by the β-secretase generating the C-terminal fragment (CTF) of 99 amino acids (C99), and by the *γ*-secretase releasing Aβ peptide, and the APP intracellular domain (AICD) \[[@ref002]\]. Cleavage of AβPP by α-secretase precludes the formation of Aβ peptides and leads to the generation of another CTF of 83 amino acids (C83) \[[@ref003]\].

Aβ peptides are generated extracellularly, but also within intracellular organelles such as the endoplasmic reticulum (ER) and mitochondria. AβPP is folded and modified in the ER and transported through the Golgi complex to the plasma membrane. It was proposed that Aβ is generated in the ER lumen as a result of deficits in axonal transport \[[@ref005]\]. Aβ oligomers (considered to be the most toxic forms of Aβ) accumulate in the ER in hippocampal neurons and thereby, likely lead to cell death in transgenic mice expressing AβPP mutant \[[@ref006]\]. Association of AβPP with mitochondria was also reported by several groups \[[@ref007]\]. Aβ was shown to accumulate into mitochondria prior to extracellular plaques and in a time-dependent manner, leading to mitochondrial damage \[[@ref010]\]. In addition, different components of the *γ*-secretase complex have been located in different subcellular compartments, including the ER and mitochondria \[[@ref009]\].

Physical association between the ER and mitochondria, also known as mitochondria-associated membranes (MAMs), play important roles in various cellular housekeeping functions such as phospholipids-, glucose-, cholesterol-, and fatty-acid- metabolism, as well as calcium signaling \[[@ref017]\]. The hypothesis stating that AD could be a disorder linked to MAMs alterations started to emerge only in the last 6 years \[[@ref019]\]. In this study, we show that AβPP and its catabolites accumulate in MAMs and increase ER-mitochondria contact sites. We also evidence that both β-secretase and *γ*-secretase complex are present and may harbor enzymatic activities in MAMs. Of most importance, we document increased neutral lipid accumulation in cellular models of AD, which was reversed by inhibiting β- or *γ*-secretases. A proteomic approach revealed the protein interactome of AβPP and its catabolites with key proteins of MAMs controlling mitochondria and ER functions.

MATERIAL AND METHODS {#sec0010}
====================

Cells {#sec0015}
-----

Human SH-SY5Y neuroblastoma cells (CRL-2266, ATCC) stably expressing pcDNA3.1 (control), wild type human AβPP (APPwt), or human AβPP harboring the double Swedish mutations (APP~swe~: APPKM670/671NL) constructs were generated as already described \[[@ref022]\]. Polyclonal stable lines were maintained in DMEM containing 10% FBS in the presence of 400 μg geneticin (Gibco).

Mock-transfected or APP695~LDN~-expressing CHO cells were obtained by stable transfection of pcDNA4 empty vector (Control), wild type hAPP695 cDNA or harboring the London mutation (APP~LDN~: APPV642I) and subcloned in pcDNA~4~ vector. Single clones were maintained in DMEM containing 10% FBS, sodium hypoxanthine-thymidine supplement, and 300 μM proline as already described \[[@ref023]\].

Cells were treated overnight (20 h) with β- or *γ*-secretase inhibitors. *γ*-secretase inhibitor ELND006 was used at 5 μM final concentration and vehicle (methylcellulose/polysorbate 80; Sigma-Aldrich) was used as control \[[@ref024]\]. β-secretase inhibitor (Eli Lilly's inhibitor LY288672 \[[@ref026]\], synthesized by Elan Pharmaceutical) was used at 30 μM final concentration prepared in DMSO. Vehicle was used as control since no difference was observed as compared to cells treated with DMSO.

Mice {#sec0020}
----

We used brains isolated from double-transgenic APP~23~xPS~45~ mice (B6-Tg *hAPP751 K670* *N/M671* *L*×*PS1 G384A* mThy1). These mice were obtained through Material Transfer Management from Novartis. To generate APP~23~xPS~45~ mice, we crossed APP~23~ transgenic line overexpressing hAβPP with the Swedish double mutation at positions 670/671 \[*hAPP751: K670* *N/M671L*\], with PS~45~ transgenic line overexpressing human PS1 carrying G384A mutation \[hPS1: G384A\] \[[@ref027]\]. Both lines are driven by a Thy-1 promoter and were developed in *C57BL/6* genetic background. Control wild type (WT) mice were from the same genetic background.

Ethics statements {#sec0025}
-----------------

*In vivo* experiments were performed in accordance with relevant guidelines and regulations established by the European community council (Directive of November 24, 1986), and approved by Nice University Animal care and use Committee, and the National Council on animal care of the Ministry of Health (Project n°: NCE/2013-152). Mice were housed in SPF animal facility.

Cellular fractionation {#sec0030}
----------------------

Cell fractionation was performed using SH-SY5Y and CHO cell lines, and brains dissected from WT, APP~23~, PS~45~, and APP~23~xPS~45~ mice using an optimized protocol to isolate subcellular fractions from tissues and cells \[[@ref028]\]. Cells (≈10^9^) were harvested, washed by centrifugation at 500×*g* for 5 min with PBS. Cells or brains (*n* = 5 for each mice group) were resuspended in homogenization buffer (225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl pH 7.4, 0.1 mM EGTA) and gently disrupted by Dounce homogenization at 4°C. The homogenate was centrifuged twice at 600×*g* for 5 min to remove nuclei and unbroken cells, and then the supernatant was centrifuged at 10 300×*g* for 10 min to pellet crude mitochondria (Mc). The resultant supernatant was centrifuged at 20 000×*g* for 30 min at 4°C. The pellet consists of lysosomal and plasma membrane fractions. Further centrifugation of the obtained supernatant at 100 000×*g* for 90 min (70-Ti rotor; Beckman, France) at 4°C results in the isolation of ER (pellet) and cytosolic fraction (supernatant). The crude mitochondrial (Mc) fraction, resuspended in MAM isolation buffer (250 mM mannitol, 5 mM HEPES pH 7.4 and 0.5 mM EGTA), was subjected to Percoll gradient centrifugation (Percoll medium: 225 mM mannitol, 25 mM HEPES pH 7.4, 1 mM EGTA, and 30% vol/vol Percoll) in a 10-ml polycarbonate ultracentrifuge tube. After centrifugation at 95,000 ×*g* for 30 min (SW40 rotor; Beckman, France), a dense band containing purified mitochondria (Mp) was recovered approximately 3/4 down of the tube, resuspended in MAM isolation buffer and washed by centrifugation at 6300×*g* for 10 min to remove the Percoll and finally resuspended in small volume of MAM isolation buffer. The MAMs, containing the structural contacts between mitochondria and ER, collected from the Percoll gradient as a diffuse white band located above the mitochondria, were diluted in MAM isolation buffer and centrifuged at 6300×*g* for 10 min; then the supernatant was further centrifuged at 100 000×*g* for 90 min (70-Ti rotor, Beckman) to pellet the MAMs fraction.

SDS-PAGE analysis {#sec0035}
-----------------

To detect Aβ peptide, protein extracts (40 μg) were incubated with 70% formic acid (Sigma) and Speed Vac evaporated for 40 min. The pellets were dissolved in 1 M Tris pH 10.8, 25 mM Betaine and diluted in 2x Tris-Tricine loading buffer (125 mM Tris-HCl pH 8.45, 2% SDS, 20% Glycerol, 0.001% Bromophenol blue, and 5% β-mercaptoethanol). Proteins were resolved by 16.5% Tris-Tricine SDS-PAGE, transferred onto PVDF membranes, and incubated overnight with specific antibodies as specified in legends. All the other proteins were resolved by Tris-Glycine SDS-PAGE following standard procedures.

Antibodies {#sec0040}
----------

Aβ, C99, and full length AβPP were detected using 6E10 antibody (Covance) recognizing 1-16 residues of Aβ. AβPP C-terminal fragments (AβPP CTF: C99 and C83), were detected using AβPP C-terminal antibody (Sigma Aldrich) recognizing 676--695 residues of AβPP. Other antibodies directed toward the following proteins were as follow: Cytochrome C oxidase subunit II (Cox), and RyR (Thermo scientific); VDAC-1 (Calbiochem); HSP60, Calreticulin, and GRP75 (Santa Cruz); Chapronin 10 (Stressgen, Biotech); Nicastrin, Tom20, α-Tubulin, and β-Actin (Sigma Aldrich), SERCA2b (clone IID8), and Aph1 (Thermo Scientific Pierce Products); BACE-1 and Cytp450 (Abcam); PS1-Nter is a generous gift from Gopal Thinakaran.

Detection of Aβ by ELISA {#sec0045}
------------------------

The concentrations of Aβ~40~ and Aβ~42~ were measured in subcellular fractions by using the respective ELISA kits (Invitrogen) following the manufacturer's instructions. Briefly, 40 μg of each fraction was treated with 5 M guanidine, 50 mM HCl solution for 3-4 h at room temperature and stored at --20°C overnight. Supernatant obtained after centrifugation at 16,000 rpm for 20 min at 4°C, were diluted at \>1/10 in D-PBS-BSA 5% and used for ELISA.

In vitro α-secretase assay {#sec0050}
--------------------------

α-secretase activity was monitored as already described \[[@ref029]\]. Briefly, 20 μg of each subcellular fraction were incubated in 90 μl final volume of Tris buffer (10 mM, pH 7.5) containing α-secretase substrate (JMV2770, 100 μM) in the absence or presence of the metal chelator *o*-phenanthroline (100 μM) reported to block metalloproteases. α-secretase activity corresponds to the α-secretase inhibitor-sensitive fluorescence recorded at 320 and 420 nm as excitation and emission wavelengths, respectively.

In vitro β-secretase assay {#sec0055}
--------------------------

β-secretase activity was monitored as already described \[[@ref022]\]. Briefly, 20 μg of each subcellular fraction were incubated in a final volume of acetate buffer (25 mM, pH4.5, 100 μl) containing BACE-1 substrate \[(7-methoxycoumarin-4-yl)-acetyl-SEVNLDAEFRK (2,4-dinitrophenyl)-RRNH~2~; 10 μm; R&D Systems\] in the absence or presence of β-secretase inhibitor I (50 μm; PromoCell). BACE-1 activity corresponds to the β-secretase inhibitor I-sensitive fluorescence recorded at 320 and 420 nm as excitation and emission wavelengths, respectively.

In vitro *γ*-secretase assay {#sec0060}
----------------------------

*In vitro* *γ*-secretase assay was assessed as already described \[[@ref030]\]. Twenty μg of each subcellular fraction were resuspended in solubilization buffer (150 mM sodium citrate pH6.4 containing 3-\[(3-cholamydopropyl) dimethylammonio\]-2-hydroxy-1-propanesulfonate 1% (v/v)) supplemented with protease inhibitor mixture. All steps were performed at 4°C. Solubilized membranes were diluted once with sodium citrate buffer (150 mM pH 6.4), and with reaction buffer (150 mM sodium citrate pH 6.4, 20 mM dithiothreitol, 0.2 mg/ml BSA, 1 mg/ml egg phosphatidyl choline and 50 μg/mL recombinant C100-FLAG). The resulting reaction mix were then either incubated over constant agitation for 16 h at 37°C or stored at 4°C (negative controls). Samples were then supplemented with 2x Tris-Tricine loading buffer, boiled for 5 min and subjected to 16.5% Tris-Tricine SDS-PAGE.

Immunofluorescence analysis {#sec0065}
---------------------------

Cells grown on 25 mm round coverslips were fixed in PFA 4% solution for 10 min at room temperature. Cells were permeabilized with triton 0.5%, and non-specific binding sites were blocked for 1 h with BSA (5%). Cells were then incubated at 4°C overnight with primary antibodies diluted in BSA (5%). After 3 washes, coverslips were incubated with secondary antibodies \[fluorescent Alexa Fluor antibodies, Alexa 488- and Alexa 594- or Alexa 633-conjugated (Invitrogen; 1:1000)\] at room temperature during 1 h. Immunofluorescence images were acquired on Leica SP5 confocal microscope using excitation filters 488, 594, and 633 nm. Images were analyzed using ImageJ.

High resolution imaging {#sec0070}
-----------------------

To visualize mitochondria and ER organelle colocalization, we used GFP construct specifically targeted to the ER. Mitochondria were labeled by using 10 nM Mitotraker^®^ Deep Red dye. Z-series images acquired on Leica SP5 microscope were deconvolved. ER and mitochondria colocalization was calculated as the number of voxels (volume pixels) occupied by both signals (i.e., erGFP and Mitotraker Deep Red) over all voxels occupied by the mitochondria (i.e. Mitotraker^®^ Deep Red signal) in thresholded images \[[@ref031]\]. The spectral proprieties of these two fluorochromes allow specific identification of the two compartments and quantification of contact sites.

Electron microscopy {#sec0075}
-------------------

Cells were fixed *in situ* with 2.5% glutaraldehyde in 0.1 M phosphate buffer at room temperature (RT) for 20 min. Samples were rinsed and then post-fixed with 1% osmium tetroxide and 1% potassium ferrocyanide in 0.1 M cacodylate buffer for 1 h at RT to enhance the staining of cytoplasmic membranes. Cells were rinsed with distilled water, embedded in epoxy resin, sectioned, and examined with a Philips CM12 transmission electron microscope equipped with an Olympus SIS CCD camera. Images were acquired randomly by a blinded investigator. We counted the total number of mitochondria (*n* \> 150) in contact or not with ER in more than 10 different micrographs obtained from two different experiments. Data are presented as a percentage of mitochondria in contact with ER.

Neutral lipid staining {#sec0080}
----------------------

Cells grown on 25 mm round coverslips were fixed in PFA 4% solution for 20 min at room temperature. Fixed cells were gently rinsed with PBS 3 times to remove residual formaldehyde. Cells were stained with 1X LipidTOX™ prepared in PBS for 30 min at room temperature. Coverslips were then processed for image acquisition on Leica SP5 confocal microscope using excitation filters 488. Images were thresholded, converted to mask and analyzed using Particle analysis ImageJ plugin.

Oligomeric Aβ preparation {#sec0085}
-------------------------

Human synthetic Aβ~1--42~ (Bachem AG, Switzerland) was suspended in hexafluoroisopropanol, HFIP; Sigma--Aldrich) to 1 mM. Peptide samples were vortexed to obtain a homogenous solution, aliquoted into microfuge tubes, and lyophilized overnight under the hood. The Aβ~1--42~ peptide films were stored desiccated at --20°C until further processed. To form Aβ oligomers, peptide films were resuspended to 5 mM in DMSO, diluted in ice cold PBS. Aggregation was allowed to proceed for 24 h at 4 °C before the peptide solution was centrifuged at 14000×*g* for 10 min at 4°C. Supernatant containing oligomeric Aβ was then used at ≈5 μM.

Immunoprecipitation and in-gel digestion {#sec0090}
----------------------------------------

After preclearing with protein A-agarose (Sigma-Aldrich) (1 h, 4°C), MAM fractions (40 μg) isolated from control CHO cells and overexpressing APP~LDN~ were immunoprecipitated using 6E10 antibody (5 μg). Immunoprecipitates were recovered by overnight incubation at 4°C, and then incubated with protein A-agarose for 3 h at 4°C. Beads were washed three times with CHRIS buffer (50 mM Tris pH 8, 10% glycerol, 200 mM NaCl, 0.5% Nonidet p-40, and 0.1 mM EDTA) supplemented with protease inhibitors (Complete, Roche diagnostics) and once with PBS. Beads were then resupended in Laemli 2x buffer, heated at 95°C, and then run on Tris-Glycine PAGE. Gels were stained using Imperial Protein Stain (Thermo scientific), a ready-to-use colorimetric stain formulated with Coomassie dye.

Gel pieces containing proteins were excised and distained by adding 100 μL of H~2~O/ACN solvent (1/1). After 10 min incubation with vortexing the liquid was discarded. This procedure was repeated 2 times. Gel piece were then rinsed (15 min) with acetonitrile and dried under vacuum. Gel pieces were reswelled in 50 μL of 20 mM dithiothreitol (DTT) in NH~4~HCO~3~ 100 mM, incubated for 30 min at 56°C, and next cooled down to RT. The DTT solution was replaced with 50 μL of 55 mM of iodoacetamide in 100 mM of NH~4~HCO~3~. After 15 min incubation in the dark at room temperature, the solution was discarded and gel pieces were washed by adding successively i) 100 μL of H~2~O/ACN (1/1), repeated 2 times and ii) 100 μL of acetonitrile. Next gel pieces were reswelled in 50 μL of 50 mM NH~4~HCO~3~ buffer containing 10 ng/μL of trypsin (modified porcine trypsin sequence grade, Promega) incubated for 1 h at 4°C. Then the solution was removed and replaced by 50 μL of 50 mM NH~4~HCO~3~ buffer (without trypsin), and incubated 18 h at 37°C. After trypsin digestion the solution was transferred into an Eppendorf tube and tryptic peptides were extracted with i) 50 μL of 1% AF (acid formic) in water (10 min at RT) and ii) 50 μL acetonitrile (10 min at RT). Peptides extracts were pooled, concentrated under vacuum and solubilized in 15 μL of 0.1% TFA (trifluoroacetic acid) in water.

NanoHPLC-MALDI-TOF/TOF analysis {#sec0095}
-------------------------------

Peptide separation was carried out using a nanoHPLC offline (ultimate *3000,* Thermo Fisher Scientific) coupled with a MALDI-TOF/TOF mass spectrometer (4800 *plus*, Applied Biosystems). Peptides solution was concentrated on a μ-Precolumn Cartridge Acclaim PepMap 100 C~18~ (i.d. 5 mm, 5 μm, 100Å, Thermo Fisher Scientific) at a flow rate of 20 μL/min and using solvent containing H~2~O/ACN/TFA 98% /2% /0.04%. Next peptides separation was performed on a 75 μm i.d.×150 mm (3 μm, 100 Å) Acclaim PepMap 100 C~18~ column (Thermo Fisher Scientific) at a flow rate of 200 nL/min and with detection at 214 nm. Solvent systems were: (A) 100% water, 0.05% TFA, (B) 100% acetonitrile, 0.04% TFA. The following gradient was used *t* = 0 min 100% A; *t* = 3 min 100% A; *t* = 63 min, 80% B; *t* = 64 min, 100% B; *t* = 69 min 100% B (temperature was regulatedat 30°C).

For offline nanoHPLC-MALDI-TOF/TOF-MS and MS/MS analyses, fractions were collected on an Opti-TOF LC/MALDI target (123×81 mm, Applied Biosystems) and fractionation was done using the Probot fractionation robot (DIONEX, LC Packings). Matrix solution (α-cyano-4-hydroxycinnamic acid, 2.5 mg/mL in 50% water, 50% acetonitrile, 0.1% TFA solution) and nanoHPLC fractions were mixed (in rate 4:1, matrix:fractions) and collected every 20 s (208 fractions were collected per run).

MS spectra were recorded automatically in a mass range of 700--4000 Da resulting from 200 laser shots of constant intensity. Data were collected using 4000 series Explorer (Applied Biosystems) allowing for an automatic selection of peptide masses for subsequent MS/MS experiments. Each MS/MS spectra acquired using 1000 laser shots were further processed using 4000 series Explorer. Finally all raw data were transferred into ProteinPilot software (Applied Biosystems, MDS Analytical Technologies) and proteins identification was processed using Paragon^TM^ Algorithm. Our analyses took in consideration only peptides with confidence index 95%. This experiment was done twice.

Statistical analyses {#sec0100}
--------------------

Results are reported from at least three different experiments or as indicated. Statistical analyses were done using Student's *t*-test, or ANOVA one-way and Tukey post-test or Newman-Keuls Multicomparison post-test. *p* value \<0.05 was considered significant.

RESULTS {#sec0105}
=======

AβPP and its proteolytic products are present in MAMs fraction of *in vitro* and *in vivo* study models of AD {#sec0110}
-------------------------------------------------------------------------------------------------------------

We first aimed at establishing by subcellular fractionation, the distribution of AβPP and its proteolytic catabolites in human SH-SY5Y neuroblastoma cells stably expressing pcDNA3.1 (control) or human AβPP harboring the double Swedish mutations (APP~swe~: APPKM670/671NL) constructs. We already reported that SH-SY5Y cells expressing APP~swe~ harbor increased AβPP processing yielding the production of AβPP CTFs fragments (C99 and C83) and of Aβ peptides \[[@ref022]\].

We investigated the presence of AβPP and its proteolytic catabolites in MAMs. Although several techniques are available to isolate mitochondria, only few are specifically tuned to the isolation of MAMs, containing unique regions of ER membranes attached to the outer mitochondrial membrane and mitochondria without contamination from other organelles (i.e., pure mitochondria). We used an optimized protocol to isolate these fractions from tissues and cells \[[@ref028]\]. Subcellular fractionation procedure was validated by confirming the expression of different proteins in cellular compartments where they were known to be enriched, namely in the ER (SERCA2b, calreticulin (CRT)), in mitochondria (cytochrome oxidase subunit II (Cox), and voltage dependent anion channel 1 (VDAC1)), and in MAMs (Glucose regulated protein 75 (GRP75)) ([Fig. 1A, B](#jad-55-jad160953-g001){ref-type="fig"}). Fraction enrichment was further demonstrated by the loss of actin signal in pure mitochondria (Mp), ER, and MAMS fractions ([Fig. 1A, B](#jad-55-jad160953-g001){ref-type="fig"}). We observed AβPP and Aβ expressions in the whole homogenate (homog), in crude mitochondria (Mc), in pure mitochondria (Mp), and in ER fractions ([Fig. 1B](#jad-55-jad160953-g001){ref-type="fig"}). Interestingly, we noticed the presence of full-length AβPP and of Aβ in MAMs fraction of APP~swe~ expressing cells ([Fig. 1B](#jad-55-jad160953-g001){ref-type="fig"}). Full-length AβPP was also observed in MAMs fraction of control cells, thus indicating that both endogenous and overexpressed AβPP are present in MAMs. However, only a slight Aβ signal was noticed in control cells. This may be related to low expression level of AβPP in control cells.

We then investigated AβPP subcellular localization in a second cellular model expressing the London APP mutation (APP~LDN~: APPV642I). In fact, while the Swedish mutation increases the rate of β-cleavage and is proposed to alter the trafficking of AβPP \[[@ref032]\], the "London" mutation increases the relative amount of the more toxic Aβ~42~ produced by *γ*-cleavage, but is not proposed to alter trafficking \[[@ref033]\]; Furthermore, It was already reported that CHO cells expressing APP~LDN~ yield high levels of intracellular and secreted Aβ oligomers \[[@ref023]\], and several lines of evidence concord to demonstrate that at least part of the AD-related neurodegenerative process could be due to Aβ oligomers \[[@ref034]\]. Thus, we carried out similar analyses on control and APP~LDN~ cells ([Supplementary Figure 1A](#S1){ref-type="supplementary-material"}). We revealed the presence of full length AβPP, and its C-terminal fragments (C99 and C83), and of Aβ in the whole homogenate, and in Mc, ER, and MAMs fractions of CHO cells expressing APP~LDN~ ([Supplementary Figure 1A](#S1){ref-type="supplementary-material"}). Of most interest, we also revealed supplementary bands ([Supplementary Figure 1A](#S1){ref-type="supplementary-material"}, see (\*) symbol) likely corresponding to dimeric and low molecular oligomeric forms of Aβ in the Mc and MAMs fractions of CHO cells expressing APP~LDN~ ([Supplementary Figure 1A](#S1){ref-type="supplementary-material"}). In this model, we also observed the presence of full-length AβPP in MAMs fraction of control cells. These first set of data show that AβPP, CTFs, and Aβ are present in MAMs in two *in vitro* models of AD.

We then examined whether AβPP and Aβ could also be present in MAMs, *in vivo*. We measured expressions of AβPP and its catabolites C99, C83, and Aβ in subcellular fractions prepared from brains isolated from WT and transgenic mice expressing human AβPP harboring the double Swedish mutations (APP~swe~: APP~23~), human presenilin 1 (PS1) (component of the *γ*-secretase complex) mutation (PS~45~: G384A), or both (APP~23~xPS~45~). Cytochrome p450 (Cytp450, an ER resident protein ([Fig. 1A](#jad-55-jad160953-g001){ref-type="fig"}) was indeed enriched in the ER fraction ([Fig. 1C](#jad-55-jad160953-g001){ref-type="fig"}). Chapronin 10 (Cpn10), a mitochondrial protein ([Fig. 1A](#jad-55-jad160953-g001){ref-type="fig"}) was detected in the homogenate and Mc, and largely enriched in Mp fraction ([Fig. 1C](#jad-55-jad160953-g001){ref-type="fig"}). Both APP~23~ and APP~23~xPS~45~ showed AβPP, its C-terminal fragments (C99 and C83), and Aβ expression in MAMs fraction ([Fig. 1C](#jad-55-jad160953-g001){ref-type="fig"}). Interestingly, we also noticed the presence of C83 but to a lesser extent than C99 in WT and PS~45~ mice ([Fig. 1C](#jad-55-jad160953-g001){ref-type="fig"}). The increased C99 fragment in APP~23~ and APP~23~xPS~45~ is likely linked to the overexpression of the Swedish mutation known to increase the rate of β-cleavage \[[@ref032]\]. Finally specific ELISA approaches allowed unraveling both Aβ~1 - 40~ and Aβ~1 - 42~ peptides in MAMs fraction of APP~23~ ([Fig. 1D](#jad-55-jad160953-g001){ref-type="fig"}). We also unraveled a slightly elevated Aβ~40~/Aβ~42~ ratio in Mc, ER, and MAMs as compared to homogenate and Mp fractions. Overall, this set of data indicates that AβPP and its catabolites are present in MAMs *in vivo* ([Fig. 1C, D](#jad-55-jad160953-g001){ref-type="fig"}) in agreement with the *in vitro* data ([Fig. 1B](#jad-55-jad160953-g001){ref-type="fig"} and [Supplementary Figure 1](#S1){ref-type="supplementary-material"}).

Immunolocalization of AβPP and its catabolites in the ER, mitochondria, and MAMs {#sec0115}
--------------------------------------------------------------------------------

We then analyzed subcellular localization of AβPP and its catabolites by immunofluorescence in SH-SY5Y cells expressing APP~swe~. We investigated the extent of AβPP, and its catabolites co-localization with the ER and mitochondria by using AβPP C-ter antibody (recognizing full length AβPP, C-terminal fragments (C83 and C99), and AβPP intracellular domain (AICD)), or 6E10 antibody (recognizing full length AβPP, C99, and Aβ peptides) concomitantly with specific antibodies recognizing proteins localized in the ER (the ryanodine receptor (RyR) and Cytp450), or in the mitochondria (Tom20 and Cox). Representative images show the co-localization (yellow signal) of AβPP and its catabolites with both the ER ([Fig. 2A, C](#jad-55-jad160953-g002){ref-type="fig"}), and mitochondria ([Fig. 2B, D](#jad-55-jad160953-g002){ref-type="fig"}) markers. Similar results were obtained in CHO cells expressing APP~LDN~ using AβPP C-ter antibody ([Supplementary Figure 1B, C](#S1){ref-type="supplementary-material"}).

We then examined AβPP and its catabolites colocalization within ER-mitochondria contact sites. SH-SY5Y cells expressing APP~swe~ were immunolabeled concomitantly with AβPP C-ter, Tom20, and the ER-resident protein calreticulin (CRT) antibodies ([Fig. 2E](#jad-55-jad160953-g002){ref-type="fig"}). Merge, high magnificence images ([Fig. 2E](#jad-55-jad160953-g002){ref-type="fig"}, merge and inset), and super imposable line scan traces ([Fig. 2F](#jad-55-jad160953-g002){ref-type="fig"}) (corresponding to the red, green, and blue fluorescence signals along the red line in the inset) demonstrate co-localization of AβPP and CTFs with both ER and mitochondria. These data are in agreement with our data obtained by subcellular fractionation and further support the presence of AβPP and its metabolites in MAMs in cellular models overexpressing both the Swedish and the London mutations.

Full length AβPP as revealed by using specific antibody recognizing AβPP N-terminal epitope (APP N-ter) shows also slight co-localization with the ER ([Supplementary Figure 3A](#S3){ref-type="supplementary-material"}) and mitochondria ([Supplementary Figure 3B](#S3){ref-type="supplementary-material"}).

Using immunofluorescence and imaging, we also examined the subcellular distribution of wild type AβPP in both SH-SY5Y and CHO cells. We show the immunolocalization of WT AβPP and its metabolites in the ER (colocalization with SERCA2b) ([Supplementary Figures 3A](#S3){ref-type="supplementary-material"} and [4A](#S4){ref-type="supplementary-material"}), mitochondria (colocalization with mitochondrial HSP60) ([Supplementary Figures 3B](#S3){ref-type="supplementary-material"} and [4B](#S4){ref-type="supplementary-material"}), and MAMs ([Supplementary Figures 3C, D](#S3){ref-type="supplementary-material"} and [4C, D](#S4){ref-type="supplementary-material"}) in both SH-SY5Y([Supplementary Figure 3](#S3){ref-type="supplementary-material"}) and CHO ([Supplementary Figure 4](#S4){ref-type="supplementary-material"}) cells overexpressing wild type AβPP. The results reveal that like the Swedish and London mutated AβPP, wild type AβPP harbor partial colocalization with the ER, mitochondria, and MAMs. These data strengthen our conclusion regarding the subcellular localization and proteolytic processing of AβPP in MAMs.

β- and *γ*-secretases are present and show in vitro activities in MAMs fraction {#sec0120}
-------------------------------------------------------------------------------

We next revealed by subcellular fractionation of APP~23~ transgenic mice brains the presence of β-secretase (BACE-1) and of components of the *γ*-secretase complex (PS1, Aph1, and nicastrin) in MAMs ([Fig. 3A](#jad-55-jad160953-g003){ref-type="fig"}). *In vitro* *γ*-secretase activity assay allowed us to reveal the hydrolysis of recombinant C100 fragment at 37°C and not at 4°C (used as negative control) that yield Aβ production in the homogenate, Mc, Mp, ER, and MAMs fractions isolated from brains of APP~23~ mice ([Fig. 3B](#jad-55-jad160953-g003){ref-type="fig"}). We did not notice a difference in *γ*-secretase activity between WT and APP~23~ mice ([Supplementary Figure 5A](#S5){ref-type="supplementary-material"}). Similarly, *γ*-secretase activity was also observed in MAMs fraction isolated from CHO cells expressing APP~LDN~ ([Supplementary Figure 5B](#S5){ref-type="supplementary-material"}). In agreement with BACE-1 expression in APP~23~ MAMs ([Fig. 3A](#jad-55-jad160953-g003){ref-type="fig"}), we detect β-secretase activity in MAMs fraction in both WT and APP~23~ mice fractions ([Fig. 3C](#jad-55-jad160953-g003){ref-type="fig"}), and in control CHO cells and expressing APP~LDN~ ([Supplementary Figure 5C](#S5){ref-type="supplementary-material"}). Related to the presence of C83 (the α-secretase-derived CTF) *in vivo* ([Fig. 1C](#jad-55-jad160953-g001){ref-type="fig"}), we also measured α-secretase activity in subcellular fractions isolated form APP~23~ transgenic mice. We indeed could observe *in vitro* α-secretase activity in the homogenate, Mc, ER, and MAMs. However, the *in vitro* α-secretase activity was lower in MAMs as compared to the other fractions ([Supplementary Figure 5D](#S5){ref-type="supplementary-material"}). All over, and according to already published data \[[@ref009]\], we revealed the presence and activity of *γ*-secretase in MAMs fraction. We also provide for the first time evidences showing that BACE-1 is present in MAMs fraction and that BACE-1 and α-secretase may harbor enzymatic activities in this domain.

Increased ER and mitochondria contacts in SH-SY5Y neuroblastoma APP~swe~ cell model {#sec0125}
-----------------------------------------------------------------------------------

Increased ER-mitochondria colocalization has been reported in human-derived fibroblasts isolated from familial and sporadic AD patients and in mouse embryonic fibroblasts isolated from either PS1 or PS1 and PS2 knockout mice \[[@ref021]\]. This was also observed in cells overexpressing familial AD PS2 mutant \[[@ref035]\]. We examined herein ER-mitochondria contact sites in live cells overexpressing APP~swe~ ([Fig. 4A](#jad-55-jad160953-g004){ref-type="fig"}). For live cells imaging, the ER was visualized by transfecting GFP construct targeted to the ER (ER GFP). Mitochondria were labeled by using Mitotracker Deep red dye as already described \[[@ref031]\]. We noticed that APP~swe~ expressing cells exhibit a significant increased co-localization of the ER and mitochondria as compared to control cells (evidenced by an increase of mitochondria volume in contact with the ER versus total mitochondria volume) ([Fig. 4A](#jad-55-jad160953-g004){ref-type="fig"}). Accordingly, we also revealed increased mitochondria in contact with the ER by electron microscopy in cells overexpressing APPswe as compared to controls ([Fig. 4B](#jad-55-jad160953-g004){ref-type="fig"}).

These data demonstrate that AβPP mutation/overexpression and most likely its proteolytic products lead to increased ER-mitochondria contact sites.

The increased ER-mitochondria contacts in SH-SY5Y neuroblastoma APP~swe~ cell model may depend on mitochondrial or ER shape and volume. Supplementary experiments are necessary to fully study this issue.

Overexpression of AβPP familial mutations increases neutral lipids accumulation {#sec0130}
-------------------------------------------------------------------------------

MAM have the proprieties of an intracellular lipid raft \[[@ref021]\]. This micro-domain is also the site of phospholipid synthesis and transport between the ER and mitochondria \[[@ref036]\]. We explored the potential lipid dysfunction in relation with AβPP and its catabolites presence in the MAM and increased ER and mitochondria contacts. In particular, lipid droplets are found in close proximity with the ER and mitochondria \[[@ref037]\].

We used LipidTox Green^TM^ dye to stain and quantify neutral lipid accumulation (major components of lipid droplets). Whereas the lipidTox stain in control CHO cells reveal few positive droplets, the CHO cells expressing APP~LDN~ contained numerous lipidTox positive droplets (∼2-fold over control cells) ([Fig. 5A, B](#jad-55-jad160953-g005){ref-type="fig"}). Similar results were also observed in SH-SY5Y neuroblastoma cells expressing APP~swe~ as compared to its respective control cells ([Supplementary Figure 6A, B](#S6){ref-type="supplementary-material"}). Importantly, the increase in lipid droplets in CHO cells expressing APP~LDN~ was reversed by inhibition of β- or *γ*-secretases. As expected, both inhibitors block Aβ production ([Supplementary Figure 6C](#S6){ref-type="supplementary-material"}). However, while the inhibitor of β-secretase strongly reduces C99 fragment production, inhibitor of *γ*-secretase enhances the accumulation of this fragment ([Supplementary Figure 6C](#S6){ref-type="supplementary-material"}). Based on these results, we may postulate that lipid droplets accumulation in our study models is likely linked to the production of Aβ peptides instead of CTFs.

We further demonstrate the specificity of our data regarding the reduction of neutral lipid accumulation obtained with β- and *γ*-secretase inhibitors observed in CHO cells expressing the London AβPP mutant. First, we analyzed neutral lipid accumulation in naïve SH-SY5Y cells upon the application of exogenous oligomeric Aβ ([Fig. 5C, 5D](#jad-55-jad160953-g005){ref-type="fig"}). We could indeed show that the treatment with exogenous oligomeric Aβ leads to increased neutral lipid accumulation ([Fig. 5C, D](#jad-55-jad160953-g005){ref-type="fig"}). However, since our Aβ preparation contains both monomeric and oligomeric forms of Aβ ([Fig. 5E](#jad-55-jad160953-g005){ref-type="fig"}), we cannot conclude whether neutral lipids accumulation is linked to either monomeric or oligomeric Aβ ([Fig. 5E](#jad-55-jad160953-g005){ref-type="fig"}). Second, we analyzed neural lipid accumulation in mouse embryonic fibroblasts (MEF) isolated from wild type (expressing endogenous AβPP) (WT MEF), or invalidated for AβPP and its family member APLP2 (referred to as APP-TKO MEF) \[[@ref039]\]. We established that knock out of AβPP did not affect neutral lipid accumulation ([Supplementary Figure 6D](#S6){ref-type="supplementary-material"}). Importantly, we did not notice an effect of both β- and *γ*-secretase inhibitors neither in WT MEF, nor in APP-TKO MEF cells ([Supplementary Figure 6D](#S6){ref-type="supplementary-material"}).

All over, these data demonstrates that neutral lipid accumulation is likely linked to AβPP overexpression and processing and to Aβ production.

Protein interactome of AβPP and its catabolites in MAMs {#sec0135}
-------------------------------------------------------

Since we showed that AβPP is present and is processed in MAMs likely contributing to increased ER-mitochondria contact sites, we hypothesized that AβPP and its catabolites may thus interact with proteins localized in this micro-domain. We used immunoprecipitation combined to proteomic approach to reveal AβPP and its catabolites protein interactome in MAMs. By using 6E10 antibody, we expected to immunoprecipitate MAMs proteins interacting directly or indirectly with AβPP holoprotein, C99, and/or Aβ peptides. To exclude false positives due to adsorption of MAMs proteins with IgG beads, we incubated MAMs fractions isolated from CHO cells expressing pcDNA4 (Control) or APP~LDN~ with IgG beads alone ([Supplementary Figure 7](#S7){ref-type="supplementary-material"}). We validated our experimental procedure by revealing AβPP peptides (accession number: P12023) in MAMs fraction isolated from APP~LDN~ CHO cells but not in CHO control cells, thus providing a positive control of our experimental protocol ([Supplementary Figure 8](#S8){ref-type="supplementary-material"}).

We specifically immunoprecipitated 135 proteins from CHO APP~LDN~ MAM fraction (obtained in 6E10 immunoprecipitate conditions, but not in samples incubated with IgG beads alone) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"}). In the analyses, we excluded IgG and ribosomal proteins. Among immunoprecipitated proteins from CHO APP~LDN~ MAMs fraction, 39 were also identified in CHO control MAMs fraction. The common proteins identified in both samples may reflect MAMs proteins interacting with full length AβPP rather than those interacting with C99 and Aβ peptides. Indeed, the amount of AβPP catabolites was clearly lower in control as compared to APP~LDN~ MAMs fraction ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}).

We analyzed the subcellular localization and biological functions of the 96 unique proteins obtained in CHO APP~LDN~ MAMs fraction by using gene onthology (GO) annotation and UniProt (Universal Protein Resource) database. In this study, we exclude from the analysis proteins showing nuclear, extracellular or microtubule localization. We then determined that 38 proteins are resident in mitochondria (44%); 23 proteins have ER localization (27%), 12 proteins are mainly cytosolic (14%), 7 proteins are found in lysosomes, Golgi apparatus, and endosomes (8%), and 6 proteins are associated with the plasma membrane (7%) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"}). It is important to note that mitochondria and ER comprise 71% of the total immunoprecipitated proteins. However, proteins associated with other organelles should not be discounted as contaminants since the plasma membrane, Golgi apparatus, and lysosomes all have tight association with the ER or mitochondria and may execute fundamental cellular functions in these contact microdomains \[[@ref040]\].

We then analyzed the types of function of the proteins identified. Of most interest, the identified molecular functions ([Supplementary Figure 7](#S7){ref-type="supplementary-material"}) are mostly attributable to MAMs functions \[[@ref041]\]. We focused on the four most significant biological processes: 1) mitochondrial function and transport (*n* = 23) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 1](#jad-55-jad160953-t001){ref-type="table"}); [2](#jad-55-jad160953-t002){ref-type="table"}) protein synthesis, maturation, folding, processing, and degradation (*n* = 18) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 2](#jad-55-jad160953-t002){ref-type="table"}); [3](#jad-55-jad160953-t003){ref-type="table"}) vesicle formation and trafficking (*n* = 12) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 3](#jad-55-jad160953-t003){ref-type="table"}); and [4](#jad-55-jad160953-t004){ref-type="table"}) fatty-acid metabolism (*n* = 10) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 4](#jad-55-jad160953-t004){ref-type="table"}). The remaining pathways correspond to proteins implicated in mitochondria and ER structure (*n* = 3), apoptosis (*n* = 2), cellular signaling (*n* = 7), and other metabolic pathways (*n* = 4) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and[Table 1](#jad-55-jad160953-t001){ref-type="table"}).

Protein interactome related to mitochondrial function {#sec0140}
-----------------------------------------------------

The identified mitochondrial proteins (*n* = 23) are implicated in mitochondrial respiratory chain complexes (*n* = 9), mitochondrial transport (*n* = 6), and mitochondrial metabolism (*n* = 8) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 1](#jad-55-jad160953-t001){ref-type="table"}). Interestingly, 6 out of 10 isolated mitochondrial respiratory chain proteins are components or chaperone proteins of the mitochondrial complex I. We also identified Cytochrome b-c1 complex subunit1 (component of the mitochondrial respiratory chain complex III), and two components of the mitochondrial ATP synthase complex ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 1](#jad-55-jad160953-t001){ref-type="table"}). The protein interactome of AβPP and its catabolites related to mitochondrial function include also proteins implicated in mitochondrial metabolism (e.g., Acyl-CoA, and coenzyme Q biosynthesis) ([Table 1](#jad-55-jad160953-t001){ref-type="table"}). In accordance with already reported data, our approach allowed us to identify proteins implicated in mitochondrial transport (e.g., TIM, and TOM complexes) \[[@ref008]\] ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 1](#jad-55-jad160953-t001){ref-type="table"}). This result could be considered as a positive control validating our experimentalprocedure.

Protein interactome related to protein synthesis, maturation, folding, processing, and degradation {#sec0145}
--------------------------------------------------------------------------------------------------

We identified different proteins implicated in ER protein maturation (e.g., glycosylation and signal peptidase complex), protein folding (e.g., inhibition of protein aggregation of misfolded proteins, protein quality control), and protein processing and degradation (e.g., peptidases, proteases) ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 2](#jad-55-jad160953-t002){ref-type="table"}). The protein interactome includes also chaperone proteins inhibiting the aggregation of misfolded proteins (e.g., the protein disulfide-isomerase A4, the protein disulfide-isomerase A6, and the peptidyl-prolyl cis-isomerase FKBP11), or implicated in the ER quality control (e.g., the protein sel-1 homolog 1, and the DnaJ homolog subfamily B member 11). Interestingly, we also identified proteins implicated in mitochondrial protein translation, and the mitochondrial presequence protease involved in the degradation of mitochondrial transit peptides ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 2](#jad-55-jad160953-t002){ref-type="table"}).

Protein interactome related to vesicle formation and trafficking {#sec0150}
----------------------------------------------------------------

In addition to the mitochondria, the ER is associated with different subcellular domains that execute divers function such as vesicular traffic \[[@ref040]\]. As a matter of fact, we identified a class of AβPP protein interactome (*n* = 12) including proteins implicated in vesicle formation and trafficking ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 3](#jad-55-jad160953-t003){ref-type="table"}). These include Ras-related family proteins (Rab-10, Rab18, and Rab1b) implicated in ER-Golgi transport and vesicular traffic, and Praf2 (PRAF1 family protein 2) known to interacts with numerous Rab GTPases thus assisting in the packaging of Rab proteins into vesicles for the transport to target compartments \[[@ref045]\]. We also revealed other proteins implicated in vesicular transport namely the transmembrane emp24 domain containing proteins (Tmed2, Tmed10, and Tmed1) and Arl8b (an Arf-like GTPase being a critical regulator of cargo delivery to lysosomes). We also revealed in the protein interactome Flotillin 1, known to be a scaffolding protein within caveolar membranes and to interact with lipid rafts \[[@ref047]\].

Protein interactome related to fatty-acid metabolism {#sec0155}
----------------------------------------------------

We classified a fourth cellular pathway including proteins (*n* = 10) implicated in fatty-acid metabolism ([Supplementary Figure 7](#S7){ref-type="supplementary-material"} and [Table 4](#jad-55-jad160953-t004){ref-type="table"}). This includes proteins implicated in fatty-acid elongation or modification (Hsd17b12, Acot1, Far1), fatty-acid beta-oxidation (Acaa2, Hadhb, and Acad9), sterol and cholesterol biosynthesis (Nsdh1, Cyp51a1, Lss), and sphingolipid metabolism (Sptlc1). Based on GO annotation, these proteins are mostly localized in the ER (Hsd17b12, Nsdhl, Sptlc1, Cyp51a1, and Lss), or in the mitochondria (Acot1, Acaa2, Far1, and Hadhb,and Acad9). Nsdhl may be also localized in lipid droplets ([Table 4](#jad-55-jad160953-t004){ref-type="table"}).

All over, these analyses identify potential new AβPP and its catabolites interactors in MAMs. However, a dedicated study is necessary to confirm specific direct or indirect interactions of AβPP or its catabolites with these proteins and their role in MAMs alteration in AD.

DISCUSSION {#sec0160}
==========

We used both biochemical and imaging approaches to demonstrate the presence of AβPP and its catabolites in MAMs in *in vitro* and in *in vivo* AD-like models. It is well established that AβPP is synthesized in the ER \[[@ref049]\]. Recent studies reported that AβPP is also associated with mitochondria in AD affected neurons \[[@ref050]\]. This was further supported by the presence of AβPP catabolites (i.e., Aβ, C99, and AICD) in the mitochondria \[[@ref009]\]. We report in this study AβPP localization, and processing in MAMs. These results were obtained in two distinct cellular systems (SH-SY5Y and CHO cells) expressing wild type AβPP or harboring two different familial mutations (APP~swe~ and APP~LDN~) thus demonstrating that the observed presence and processing of WT or mutated AβPP in MAMs is not linked to a specific cell type and not to a specific familial AβPP mutation. This may also reveal that the subcellular localization and proteolytic processing of AβPP in MAMs was not linked to AD familial cases but may also be observed in sporadic cases of AD. These data also suggest that even if trafficking of AβPP may vary according to the mutation, transit through MAMs compartment where AβPP undergo cleavage is a common denominator independent of the nature of the AβPP species.

We also revealed the presence and activity of α-, β-, and *γ*-secretases in the MAMs. *γ*-secretase was shown to exert its activity in the plasma membrane but also in other intracellular compartments such as the trans-Golgi network, lysososmes, pure mitochondria fraction, and MAMs \[[@ref016]\]. However, it is important to emphasize that even if *γ*-secretase complex has been found in mitochondria \[[@ref016]\], the putative generation of intra-mitochondrial Aβ and C99 remains puzzling, given the C-terminus-out orientation of AβPP in the outer mitochondrial membrane. A hypothetical model has been proposed stating that Aβ may be produced at the interface between the ER and mitochondria and then transferred to the mitochondria via the TOM import machinery \[[@ref009]\]. Another gap to envision the production of Aβ in mitochondria was the demonstration of the presence of active β-secretase (BACE-1) in mitochondria or in MAMs. Importantly, we report herein and for the first time the presence of BACE-1 in crude mitochondria and MAMs fractions. Current knowledge on AβPP and BACE-1 trafficking indicates that plasma membrane and endosomes are likely the major sites of BACE-1-mediated cleavage of AβPP \[[@ref057]\]. Mature BACE-1 localizes largely within plasma membrane cholesterol-rich lipid rafts \[[@ref057]\], and replacing the BACE-1 transmembrane domain with a glycosylphosphatidylinositol anchor extensively targets BACE-1 to lipid rafts and substantially increases Aβ production \[[@ref059]\]. In addition, various types of lipids stimulate BACE-1 activity \[[@ref060]\]. Interestingly, a recent study revealed that MAMs behave as a detergent-resistant lipid raft-like domain, consistent with the presence and activity of β- and *γ*-secretase in rafts \[[@ref021]\]. In accordance with the presence of α-CTF fragment in MAMs, we also could measure an *in vitro* α-secretase activity in this compartment in mice brains ([Supplementary Figure 5D](#S5){ref-type="supplementary-material"}). Other experiments are still needed to further characterize expression and subcellular distribution and trafficking of α-secretase *in vitro* and *in vivo*. We must take into account that both β- and *γ*-secretases harbor optimal activities in acidic compartments and that the pH of the ER is almost neutral (pH 7.2), and that of mitochondria matrix is markedly alkaline (pH 8) \[[@ref064]\]. Thus, it remains not clear how these enzymes may function in the ER, mitochondria, and MAMs compartments in intact cells. One may postulate that AβPP, or at least its C-terminal fragments (C99/C83), and BACE-1 are transported to the ER-mitochondria contact sites through a mechanism implicating retrograde vesicular trafficking. Indeed, we identified different proteins related to vesicle formation and trafficking in the protein interactome data of MAMs fraction isolated from CHO cells expressing APP~LDN~ ([Table 3](#jad-55-jad160953-t003){ref-type="table"}). Dedicated experiments are necessary to confirm this hypothesis and to further explore the molecular mechanisms underlying BACE-1 localization and *in situ* function in MAMs.

We report an increased ER-mitochondria contact sites in SH-SY5Y cells overexpressing APP~swe~. Accordingly, an increased ER-mitochondria connectivity was detected in human fibroblasts isolated from individuals with familial AD mutations as well as sporadic AD cases, and in MEFs isolated from mice simple or double knockout for PS1 or PS2 \[[@ref021]\]. Similar results were obtained in neuroblastoma cells expressing familial AD-linked PS2 mutations \[[@ref035]\]. Interestingly, increased ER-mitochondria connectivity was also reported in a transgenic AD mouse model expressing mutant tau protein \[[@ref065]\], and most recently, in cells exposed to apolipoprotein E (ApoE4), a major risk factor for developing sporadic AD \[[@ref066]\]. These results and our data may lead to consider MAMs structural alteration as a common denominator underlying the pathogenesis of AD associated to both sporadic and APP/PS-linked familial AD mutations. In agreement with these data, the proteomic approach revealed potential AβPP interactors implicated in the regulation of mitochondrial and ER structure (Dnajc11 and atlastin 3 respectively) ([Supplementary Table 1](#S9){ref-type="supplementary-material"}) \[[@ref067]\]. Accordingly, postmortem analysis of human AD brain and those of AD mouse models showed altered expression levels of PACS2 and Sigma1R, thus further establishing deregulated MAMs as a hallmark of AD \[[@ref070]\]. Moreover, it is interesting to note that AβPP processing relies on intact ER-mitochondria crosstalk \[[@ref021]\]. Thus, cells deficient of MFN2 show diminished MAM function in terms of lipid metabolism and reduced *γ*-secretase activity by approximately 50% \[[@ref021]\]. In turn, exposing hippocampal neurons or neuroblastoma cells to Aβ enhances ER-mitochondria contacts \[[@ref070]\]. These observations are in favor of a vicious cycle where AβPP is processed in MAMs, and its derivative catabolites enhance ER-mitochondria communication and function.

We analyzed a second aspect of MAMs function in AD by combining immunoprecipitation and proteomic mass spectrometric analysis to identify molecules that associate with AβPP and its proteolytic products in MAMs. This approach allows the unbiased and extensive exploration of all possible direct or indirect protein interactors. Nevertheless, we may consider some limitations of the approach used here namely the difficulty to identify interactors of lower expression. This approach failed also to reveal components of *γ*-secretase and/or β-secretase in MAM proteome analyses. This may be explained by the limitation of immunoprecipitation approach and/or to instable interaction of AβPP and its cleaving enzymes. Although, the strength of our data is supported by the identification of AβPP interactors described in previous studies using distinct experimental approaches (i.e., TIM/TOM complex) \[[@ref008]\]. Furthermore, we also revealed new protein partners belonging to cellular pathways known to participate to AD pathogenesis. Interestingly, six out of nine of AβPP and its catabolites interactome related to mitochondrial respiratory chain complexes are components or chaperone of complex I. Previous studies have revealed that Aβ may cause both a selective defect in complex I activity associated with an increase of intracellular reactive oxygen species \[[@ref072]\]. We also unraveled an interaction of AβPP and or its catabolites with the mitochondrial ATP synthase (complex V). Interestingly this enzyme shows reduced activity in AD affectedbrains \[[@ref074]\].

We revealed the interaction of AβPP and its catabolites with several proteins implicated in protein synthesis, maturation, folding, processing, and degradation. Several studies have suggested that altered maturation, processing, and degradation of AβPP holoprotein may drive the availability of AβPP for Aβ generation \[[@ref075]\]. It was also suggested that different PPIases regulate Aβ production, or the toxicity associated with Aβ \[[@ref079]\]. Concerning mitochondria, we showed that AβPP and its catabolites may directly or indirectly interact with mitochondrial presequence protease (PreP, GN: pitrm), a pitrilysin metallopeptidase 1 implicated in the degradation of mitochondrial transit peptides after their cleavage. PreP has been shown to degrade various Aβ peptides thus clearing mitochondrial (Aβ) \[[@ref080]\]. Accordingly, increased neuronal PreP activity attenuates neuroinflammation and improves mitochondrial and synaptic function in AD mice model \[[@ref082]\].

Finally, we delineate in this study the potential interaction of AβPP and its catabolites with different proteins related to fatty-acid metabolism. Accordingly, we show increased neutral lipids accumulation in both neuroblastoma and CHO cells expressing APP~swe~ or APP~LDN~. Neutral lipids accumulation was reported in different AD study models including PS-mutant MEFs, PS double knockout MEFs, fibroblasts from familial AD patients \[[@ref021]\], and more recently fibroblasts exposed to ApoE4 conditioned media \[[@ref066]\]. We also revealed that neutral lipids accumulation in our study models is likely linked to Aβ peptides rather to C99 fragment. A more dedicated study is necessary to investigate the molecular mechanisms underlying lipid droplets accumulation in AD. In particular, lipid droplets are found in close proximity with the ER and mitochondria \[[@ref037]\], and the functions of these interactions are still largely unknown. It is, however, noticeable that proteolytic cleavage of AβPP is tightly regulated by several lipids such as cholesterol and sphingolipids. In turn, Aβ as well as other AβPP processing products play an essential role in regulating lipid homeostasis \[[@ref084]\]. Moreover, *in vitro* studies have shown that fatty acids may affect Aβ secretion \[[@ref085]\].

In summary, our data extends the previous studies suggesting MAMs as an important contributor to AD pathogenesis. Maintenance and tight regulation of MAM structure and function could be envisioned as potential therapeutic strategies for AD.

Supplementary Material
======================

###### Supplementary Figure 1

Presence of AβPP and its catabolites in the ER, mitochondria, and MAM of CHO cells expressing APP~LDN~. A) Representative SDS-PAGE of subcellular fractions isolated from CHO cells expressing pcDNA4 empty vector (Control) or hAPP695 with London mutation (APPV642I: APP~LDN~). We load 40 μg of total homogenate (homog), Crude mitochondria (Mc), the endoplasmic reticulum (ER), and MAMs fractions. AβPP, C99 and Aβ were detected by 6E10 antibody. (\*) shows dimeric and low molecular weight oligomeric Aβ. AβPP C-terminal fragments (C99 and C83) were detected by AβPP C-ter antibody. B) Immunostaining of CHO cells expressing APP~LDN~ with AβPP C-ter antibody and SERCA2b. C) Immunostaining of CHO cells expressing APP~LDN~ with AβPP C-ter antibody and Tom20. Merge images and magnified overlay show green and red signals and colocalization in yellow. Scale bars represent 20 μm.
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Click here for additional data file.

###### Supplementary Figure 2

Immunolocalization of full length AβPP in the ER and mitochondria. A,B) Immunostaining of SH-SY5Y cells expressing AβPP~swe~ with AβPP N-ter antibody recognizing full length AβPP and Cytp450 and Cox (B). Merge images and magnified overlay show green and red signals and colocalization in yellow. Scale bars represent 10 μm.
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Click here for additional data file.

###### Supplementary Figure 3

Wild type AβPP and its catabolites colocalize with ER and mitochondria in SH-SY5Y cells. A,B) Immunostaining of SH-SY5Y cells expressing wt AβPP with C-ter antibody recognizing total AβPP and CTF (C99 and C83). SERCA2b was used to stain the ER (A). HSP60 was used to stain mitochondria (B). A,B) Merge images show green and red signals and were used to show the colocalization of AβPP and its catabolites with the ER or mitochondria (yellow signal). C) Concomitant immunostaining of SH-SY5Y cells expressing wt AβPP with C-ter, SERCA2b, and HSP60 antibodies. Merge image shows overlay of green, red, and blue signals, where colocalization is depicted in white (see magnified overlay). Scale bar represents 10 μm. D) RGB (Red, Green, Blue) profile plots of a representative line scan (red line in inset) shows the maximum intensity of Red, Green, and Blue plots observed at the same distance, and demonstrating the colocalization of Red (SERCA2b), Green (C-ter), and Blue (HSP60) signals.
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###### Supplementary Figure 4

Wild type AβPP and its catabolites colocalize with ER and mitochondria in CHO cells. A,B) Immunostaining of CHO cells expressing wt AβPP with C-ter antibody recognizing total AβPP and CTF (C99 and C83). SERCA2b was used to stain the ER (A). HSP60 was used to stain mitochondria (B). A,B) Merge images show green and red signals and were used to show the colocalization of AβPP and its catabolites with the ER or mitochondria (yellow signal). C) Concomitant immunostaining of CHO cells expressing wt AβPP with C-ter, SERCA2b, and HSP60 antibodies. Merge image shows overlay of green, red, and blue signals, where colocalization is depicted in white (see magnified overlay). Scale bar represents 10 μm. D) RGB (Red, Green, Blue) profile plots of a representative line scan (red line in inset) shows the maximum intensity of Red, Green, and Blue plots observed at the same distance, and demonstrating the colocalization of Red (SERCA2b), Green (C-ter), and Blue (HSP60) signals.
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###### Supplementary Figure 5

α-, β-, and γ-seceretase activities in MAMs fraction. A) Cell-free Aβ production from recombinant C100 peptide performed at 4°C (negative control) or 37°C in the presence of subcellular fractions isolated from wild type mice (WT). C100 and Aβ were detected using 6E10 antibody. B) Cell-free Aβ production from recombinant C100 peptide performed at 4°C or 37°C in the presence of subcellular fractions isolated from CHO cells expressing APP~LDN~. C100 and Aβ were detected as in (A). C) *In vitro* β-secretase specific activity in control and APP~LDN~ CHO fractions. The graph represents β-secretase specific activity obtained by subtracting residual activity in the presence of β-secretase inhibitor from total β-secretase activity and is expressed in fluorescent units (FU)/hour (h)/mg of proteins of each fraction. Data are presented as Mean ± S.E.M. obtained from 3 independent experiments. Differences are statistically non significant using ANOVA one way and Newman-Keuls Multicomparaison post-test. D) *In vitro* α-secretase specific activity in APP~23~ brain fractions. The graph represents α-secretase specific activity obtained by subtracting residual activity in the presence of α-secretase inhibitor from total α-secretase activity and is expressed in fluorescent units (FU)/hour (h)/mg of proteins of each fraction. Data are presented as Mean ± S.E.M. obtained from 3 independent experiments. \*\*\*p value\<0.001 calculated using ANOVA one way and Newman-Keuls Multicomparaison post-test.
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###### Supplementary Figure 6

Detection of Lipid droplets in control and AβPP~swe~ SH-SY5Y expressing cells and in wild type and APP-TKO MEF. A) Representative images showing neutral lipids staining in SH-SY5Y control cells or expressing AβPP~swe~. Scale bars represent 25 μm. B) The graph shows the quantification of lipid droplets (mean ± S.E.M. number of puncta)/cell. The number of analyzed cells is indicated for each condition and was obtained from at least three independent experiments. \*p value \<0.05, using Student t-test. C) Western blot of AβPP and its catabolites in SH-SY5Y cells expressing AβPP~swe~ treated with vehicle (Control) or with γ -secretase or β-secretase inhibitors for 20 h and revealed on total extracts. AβPP, C99, and Aβ were detected using 6E10 Antibody. Actin was used as loading controls. Low and high expositions are shown. D) Graph showing neural lipid accumulation (mean ± S.E.M. number of puncta)/cell) in mouse embryonic fibroblasts (MEF) isolated from wild type (expressing endogenous AβPP) (MEF WT), or triply invalidated for AβPP and its isoforms APLP1 and APLP2 (APP-TKO MEF). Cells were non treated (NT) or treated with vehicle or with β- or γ-secretase inhibitors. The number of analyzed cells is indicated for each condition and was obtained from at least three independent experiments. No significance was obtained between the different conditions.
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###### Supplementary Figure 7

Protein interactome of AβPP and its catabolites in MAMs. A) Chart flow of the protocol used to analyze protein interactome of AβPP and its catabolite in MAM fraction. 40 μg of MAMs fraction isolated from CHO cells expressing pcDNA4 (Control) or AβPP~LDN~ were subjected to immunoprecipitation (IP) with 6E10 antibody. As control, MAMs fractions were also incubated with IgG beads in the absence of 6E10 antibody. Samples were fractionated on SDS-PAGE. This later was stained and subjected to in-gel trypsin digestion. Proteomic analysis was performed on different bands (ranging from 15 kDa to 250 kDa) by Nano-LC/MS/MS. Specific peptides were considered those obtained in 6E10 immunoprecipitate conditions, but not in samples incubated with IgG beads alone. B) Representative SDS-PAGE showing the loading of different experimental conditions. C) Subcellular distribution of cellular unique peptides identified by Nano-LC/MS/MS from control and AβPP~LDN~ MAM fractions subjected to immunoprecipitation with 6E10. Organelle association for each protein was determined by GO (gene onthology) annotation and UniProt (Universal Protein Resource) database. D) Biological functions of the identified unique peptides determined by GO annotation and UniProt (Universal Protein Resource) database. The number of identified proteins for each pathway is indicated.
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###### Supplementary Figure 8

Sequence and localization of AβPP unique peptides identified by NanoHPLC-MALDI-TOF/TOF analysis. The protein accession number (P12023) was obtained by Swiss-Prot/Trenbl corresponding to Amyloid beta A4 protein on UniProt database. Matched MS/MS peptides are depicted in Green ≥ 95%. (%) represents confidence index.
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###### Supplementary Table
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![AβPP and its catabolites are present in MAMs fraction. A) Scheme representing ER-mitochondria contact sites and the molecular markers of ER and mitochondria used. MRC, mitochondrial respiratory chain. B, C) Representative SDS-PAGE of subcellular fractions isolated from: (B) SH-SY5Y neuroblastoma cells expressing pcDNA3.1 empty vector (Control) or hAPP695 harboring double Swedish mutations (APPKM670/671NL: APP~swe~), and (C) brains of WT mice, PS~45~, APP~23~, and APP~23~xPS~45~ transgenic mice. We load 40 μg (B) or 20 μg (C) of total homogenate (homog), Crude mitochondria (Mc), pure mitochondria (Mp), the endoplasmic reticulum (ER), and MAMs fractions. AβPP, C99, and Aβ were detected by 6E10 antibody. AβPP C-terminal fragments (C99 and C83) were detected by AβPP C-ter antibody. SERCA2b, calreticulin (CRT), and Cytochrome p450 (Cytp450) were used as loading controls for ER fraction. Cox, VDAC1, and Chapronin 10 (Cpn10) were used as loading controls for Mc and Mp fractions. GRP75 was used as loading controls for MAMs fraction. Actin and Tubulin were used as loading controls. Data are representative of 3 independent experiments for (B), and were obtained from 5 animals per group of mice and repeated twice for (C). D) ELISA of Aβ~40~ and Aβ~42~ done on subcellular fractions isolated from APP~23~ transgenic mice. Graph represents Mean±S.E.M from three experiments and expressed in pg per μg of proteins. \**p* value \<0.05, \*\**p* value \<0.01, \*\*\**p* value \<0.001 calculated using ANOVA one way and Newman-Keuls Multicomparison post-test.](jad-55-jad160953-g001){#jad-55-jad160953-g001}

![AβPP and its catabolites colocalize with ER and mitochondria. A, B) Immunostaining of SH-SY5Y APP~swe~ cells with AβPP C-ter antibody recognizing total AβPP and CTF (C99 and C83). RyR was used to stain the ER (A). Tom20 was used to stain mitochondria (B). C, D) Immunostaining of SH-SY5Y APP~swe~ cells with 6E10 antibody recognizing total AβPP, C99, and Aβ peptides. Cytp450 was used to stain the ER (C). Cox was used to stain mitochondria (D). A-D) Merge images show green and red signals and were used to show the colocalization of AβPP and its catabolites with the ER or mitochondria (yellow signal). Scale bars represent 10 μm. E) Immunostaining of SH-SY5Y APP~swe~ cells with AβPP C-ter, Tom20, and calreticulin (CRT) antibodies. Merge images show overlay of green, red and blue signals, where colocalization is depicted in white (see merge image and magnified overlay). Scale bar represents 10 μm. F) RGB (Red, Green, Blue) profile plots of a representative line scan (red line in inset) shows the maximum intensity of Red, Green, and Blue plots observed at the same distance, and demonstrating the colocalization of Red (Tom20), Green (C-ter), and Blue (CRT) signals.](jad-55-jad160953-g002){#jad-55-jad160953-g002}

![β-secretase and *γ*-secretase complex are present and active in MAMs fraction in mice brains. A) Representative SDS-PAGE of subcellular fractions isolated from APP~23~ transgenic mice as in [Fig. 1](#jad-55-jad160953-g001){ref-type="fig"} showing the expression of *γ*-seceretase complex (cleaved Presenilin 1 N-terminal fragment (PS1-NT); Anterior Pharynx-Defective 1 (Aph1); and Nicastrin (NCT)) and of β-secretase (BACE-1). B) Cell-free Aβ production from recombinant C100 peptide performed at 37°C or 4°C in the presence of subcellular fractions isolated from APP~23~ transgenic mice. C100 and Aβ were detected using 6E10 antibody. C) *In vitro* β-secretase specific activity in WT and APP~23~ mice brain fractions. The graph represents β-secretase specific activity obtained by subtracting residual activity in the presence of β-secretase inhibitor from total β-secretase activity and is expressed in fluorescent units (FU)/hour (h)/mg of proteins of each fraction. Data are presented as Mean±S.E.M. obtained from 3 independent experiments. Differences are statistically non-significant using ANOVA one-way and Newman-Keuls Multicomparison post-test.](jad-55-jad160953-g003){#jad-55-jad160953-g003}

![Increased ER-mitochondria contact sites in SH-SY5Y cells expressing APP~swe~. A) Quantitative analyses of the colocalization of ER and mitochondria in SH-SY5Y live cells expressing pcDNA3.1 \[Control (*n* = 4) or APP~swe~ (*n* = 7)\]. ER is visualized by transfecting ER GFP (green). Mitochondria are stained with Mitotracker Deep red dye (red). Merge images show overlay of green and red signals. Insets (magnified overlay) showing ER and mitochondria colocalization depicted in yellow. The graph represents the quantification of ER and mitochondria colocalization presented as percentage of total mitochondrial volume (% mean±S.E.M.). \*\**p* value \< 0.01 using Student's *t* test. Scale bars represent 5 μm. B) Representative electron microscopy micrographs of control and APP~swe~ expressing cells. Red arrows show mitochondria in contacts with ER. High magnificence of ER-mitochondria contacts is shown for APP~swe~ cells. Data are presented as % of mitochondria in contacts with ER. Quantification was obtained from a total number of mitochondria in control (*n* = 195) and in APP~swe~ expressing cells (*n* = 166). Scale bars represent 2 μm.](jad-55-jad160953-g004){#jad-55-jad160953-g004}

![Increased neutral lipid droplets accumulation in CHO cells expressing APP~LDN~. A) Representative images showing neutral lipids staining in CHO control cells or expressing APP~LDN~. Cells were treated with vehicle or with β- or *γ*-secretase inhibitors for 20 h. Scale bars represent 25 μm. B) The graph shows the quantification of lipid droplets (mean±S.E.M. number of puncta/cell). The number of analyzed cells is indicated for each condition and was obtained from at least three independent experiments. \**p* value \< 0.05, and \*\**p* value \< 0.01 using ANOVA one way and Tukey post-test. C) Representative images showing neutral lipids staining in SH-SY5Y cells non treated or treated with 5 μM oligomeric Aβ (oAβ) preparation for 20 h. Scale bars represent 10 μm. D) The graph shows the quantification of lipid droplets (mean±S.E.M. number of puncta/cell). The number of analyzed cells is indicated for each condition and was obtained from two independent experiments. \**p* value \< 0.05, using Student *t*-test. E) Representative SDS-PAGE of oligomeric Aβ (3 μM and 6 μM) preparation.](jad-55-jad160953-g005){#jad-55-jad160953-g005}

###### 

Classification of protein interactome of the AβPP and its catabolites related to mitochondrial function

  UniProt ID                                    Name^(a)^
  --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  *Mitochondrial respiratory chain complexes*   
  Q9CZ13                                        Cytochrome b-c1 complex subunit 1, mitochondrial GN = Uqcrc1
  Q8BGH2^(\*)^                                  Sorting and assembly machinery component 50 homolog GN = Samm50
  Q91VD9                                        NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial GN = Ndufs1
  Q91WD5                                        NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 2, mitochondrial GN = Ndufs2
  Q91YT0                                        NADH dehydrogenase \[ubiquinone\] flavoprotein 1, mitochondrial GN = Ndufv1
  Q9CQN1                                        Heat shock protein 75 kDa, mitochondrial GN = Trap1
  Q9CWX2                                        Complex I intermediate-associated protein 30, mitochondrial GN = Ndufaf1
  P97450                                        ATP synthase-coupling factor 6, mitochondrial GN = Atp5j
  Q9CQQ7                                        ATP synthase subunit b, mitochondrial GN = Atp5f1
  *Mitochondrial transport*                     
  Q9Z0V7                                        Mitochondrial import inner membrane translocase subunit Tim17-B GN = Timm17b
  Q8BGH2^(\*)^                                  Sorting and assembly machinery component 50 homolog GN = Samm50
  Q9CPQ3                                        Mitochondrial import receptor subunit TOM22 homolog GN = Tomm22
  Q9QZD8                                        Mitochondrial dicarboxylate carrier GN = Slc25a10
  Q9Z2Z6                                        Mitochondrial carnitine/acylcarnitine carrier protein OS = Mus musculus GN = Slc25a20
  Q9CQX2                                        Cytochrome b5 type B GN = Cyb5b
  *Mitochondrial metabolism*                    
  Q9JHI5                                        Isovaleryl-CoA dehydrogenase, mitochondrial GN = Ivd
  Q9WUM5                                        Succinyl-CoA ligase \[ADP/GDP-forming\] subunit alpha, mitochondrial GN = Suclg1
  Q9R112                                        Sulfide:quinone oxidoreductase, mitochondrial GN = Sqrdl
  Q9D2G2                                        Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial GN = Dlst
  Q60936                                        Chaperone activity of bc1 complex-like, mitochondrial GN = Adck3
  Q64521                                        Glycerol-3-phosphate dehydrogenase, mitochondrial GN = Gpd2
  Q99KI0                                        Aconitate hydratase, mitochondrial GN = Aco2
  Q9D051                                        Pyruvate dehydrogenase E1 component subunit beta, mitochondrial GN = Pdhb

UniProtID, protein accession number in Swiss-Prot/Trembl. ^(a)^Protein name given by UniProt database. ^(b)^Number of peptides matching the protein with a confidence limit of 95%. ^(\*)^A protein that have several functions. GN, gene name.

###### 

Classification of protein interactome of the AβPP and its catabolites related to protein synthesis, maturation, folding, processing and degradation

  UniProt ID                             Name^(a)^
  -------------------------------------- -----------------------------------------------------------------------------------------
  *Protein synthesis*                    
  Q8K0D5                                 Elongation factor G, mitochondrial GN = Gfm1
  Q8R2Y8                                 Peptidyl-tRNA hydrolase 2, mitochondrial GN = Ptrh2
  *Protein maturation or modification*   
  Q9DBG6                                 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 GN = Rpn2
  P46978                                 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A GN = Stt3a
  Q9R0P6                                 Signal peptidase complex catalytic subunit SEC11A GN = Sec11a
  Q9CXY9                                 GPI-anchor transamidase GN = Pigk
  *Protein folding*                      
  P08003                                 Protein disulfide-isomerase A4 GN = Pdia4
  Q922R8                                 Protein disulfide-isomerase A6 GN = Pdia6
  Q9D1M7                                 Peptidyl-prolyl cis-trans isomerase FKBP11 GN = Fkbp11
  Q9Z2G6                                 Protein sel-1 homolog 1 GN = Sel1l
  P24369                                 Peptidyl-prolyl cis-trans isomerase B GN = Ppib
  Q99KV1                                 DnaJ homolog subfamily B member 11 GN = Dnajb11
  *Protein processing and degradation*   
  Q8K411                                 Presequence protease, mitochondrial GN = Pitrm1
  Q6I6G8                                 E3 ubiquitin-protein ligase HECW2 GN = Hecw2
  O70481                                 E3 ubiquitin-protein ligase UBR1 GN = Ubr1
  O88696                                 Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial GN = Clpp
  Q9QXV0                                 ProSAAS GN = Pcsk1n
  Q9CYN2                                 Signal peptidase complex subunit 2 GN = Spcs2

UniProtID, protein accession number in Swiss-Prot/Trembl. ^(a)^Protein name given by UniProt database. ^(b)^Number of unique peptides matching the protein with a confidence limit of 95%. GN, gene name.

###### 

Classification of protein interactome of the AβPP and its catabolites related to vesicle formation and trafficking

  UniProt ID   Name^(a)^
  ------------ --------------------------------------------------------------
  Q3V009       Transmembrane emp24 domain-containing protein 1 GN = Tmed1
  Q9R0Q3       Transmembrane emp24 domain-containing protein 2 GN = Tmed2
  Q9D1D4       Transmembrane emp24 domain-containing protein 10 GN = Tmed10
  O08917       Flotillin-1 GN = Flot1
  O55100       Synaptogyrin-1 GN = Syngr1
  P35293       Ras-related protein Rab-18 GN = Rab18
  P61027       Ras-related protein Rab-10 GN = Rab10
  Q9D1G1       Ras-related protein Rab-1B GN = Rab1b
  Q61548       Clathrin coat assembly protein AP180 GN = Snap91
  Q9CQW2       ADP-ribosylation factor-like protein 8B GN = Arl8b
  Q9EQH3       Vacuolar protein sorting-associated protein 35 GN = Vps35
  Q9JIG8       PRA1 family protein 2 GN = Praf2

UniProtID, protein accession number in Swiss-Prot/Trembl. ^(a)^Protein name given by UniProt database. ^(b)^Number of unique peptides matching the protein with a confidence limit of 95%. GN, gene name.

###### 

Classification of protein intercatome of the AβPP and its catabolites related to fatty-acid metabolism

  UniProt ID   Name^(a)^
  ------------ ------------------------------------------------------------------------
  O70503       Estradiol 17-beta-dehydrogenase 12 GN = Hsd17b12
  Q9R1J0       Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating GN = Nsdhl
  O35704       Serine palmitoyltransferase 1 GN = Sptlc1
  O55137       Acyl-coenzyme A thioesterase 1 GN = Acot1
  Q8BWT1       3-ketoacyl-CoA thiolase, mitochondrial GN = Acaa2
  Q8K0C4       Lanosterol 14-alpha demethylase GN = Cyp51a1
  Q8JZN5       Acyl-CoA dehydrogenase family member 9, mitochondrial GN = Acad9
  Q922J9       Fatty acyl-CoA reductase 1 GN = Far1
  Q99JY0       Trifunctional enzyme subunit beta, mitochondrial GN = Hadhb
  Q8BLN5       Lanosterol synthase GN = Lss

UniProtID, protein accession number in Swiss-Prot/Trembl. ^(a)^Protein name given by UniProt database. ^(b)^Number of unique peptides matching the protein with a confidence limit of 95%. GN, gene name.
